Synthetic Lethal Targeting of ARID1A-Mutant Ovarian Clear Cell Tumors with Dasatinib

Rowan E. Miller1,2, Rachel Brough1,2, Ilirjana Bajrami1,2, Chris T. Williamson1,2, Simon McDade3, James Campbell1,2, Asha Kigozi1,2, Rumana Rafiq1,2, Helen Pemberton1,2, Rachel Natrajan2, Josephine Joe4, Holly Astley4, Claire Mahoney4, Jonathan D. Moore4, Chris Torrance4, John D. Gordan5, James T. Webber5, Rebecca S. Levin6, Kevan M. Shokat6,7, Sourav Bandypadhyay6, Christopher J. Lord1,2, and Alan Ashworth1,2

Abstract

New targeted approaches to ovarian clear cell carcinomas (OCCC) are needed given the limited treatment options in this disease and the poor response to standard chemotherapy. Using a series of high-throughput cell-based drug screens in OCCC tumor cell models, we have identified a synthetic lethal (SL) interaction between the kinase inhibitor dasatinib and a key driver in OCCC, ARID1A mutation. Imposing ARID1A deficiency upon a variety of human or mouse cells induced dasatinib sensitivity, both in vitro, suggesting that this is a robust synthetic lethal interaction. The sensitivity of ARID1A-deficient cells to dasatinib was associated with G1–S cell-cycle arrest and was dependent upon both p21 and Rb. Using focused siRNA screens and kinase profiling, we showed that ARID1A-mutant OCCC tumor cells are addicted to the dasatinib target YES1. This suggests that dasatinib merits investigation for the treatment of patients with ARID1A-mutant OCCC.

Introduction

Ovarian clear cell carcinomas (OCCC) comprise between 5 and 25% of all epithelial ovarian cancers and are often associated with endometriosis (1). Patients with advanced OCCC generally respond poorly to standard platinum-based chemotherapy and have a median 5-year survival rate of less than 32% (2, 3). Recently, comprehensive DNA sequencing of OCCCs has led to the identification of likely driver mutations in this disease (4, 5). The most commonly recurrent genetic event in OCCC is somatic mutation in the tumor suppressor gene ARID1A (AT-Rich-Interactive Domain-containing protein 1A) which is present in up to 57% of patients (4, 5). A significant proportion of the tumor-associated somatic ARID1A mutations in OCCC are frame-shift insertion/deletion mutations or nonsense mutations that are predicted to result in premature truncation of the protein (4, 5). In addition to being recurrently mutated in OCCC, frame-shift insertion/deletion mutations and nonsense mutations in ARID1A have also been identified in multiple other cancer types such as gastric cancer, renal clear cell cancer, and pancreatic tumors (6). Loss of ARID1A expression has also been associated with a shorter progression-free survival and resistance to platinum-based chemotherapy in OCCC patients (7).

The best-characterized role of the ARID1A protein is as a component of the BAF SWI/SNF chromatin-remodeling complex. The BAF complex plays a key role in modifying the position of nucleosomes on DNA (8–10) and in doing so likely regulates the access of additional proteins to DNA (8). The composition of the BAF complex includes: (i) an ATP-dependent DNA helicase, encoded by the SMARCA4/BRG1 or SMARCA2/BRM genes; (ii) ARID1A or ARID1B, which each encompass an ARID DNA-binding domain; and (iii) a series of additional accessory subunits such as SMARCB1, SMARCE1, and SMARC1-3. ARID1A dysfunction has been associated with a relatively diverse set of phenotypes including defects in cell differentiation, alterations in the control of cell proliferation, as well as defects in the repair of DNA (9, 10, 12, 13). However, a precise molecular understanding of how defects in ARID1A lead to each of these phenotypes is not yet clear.

Given the high prevalence of ARID1A mutations in OCCC, identifying drugs that selectively target ARID1A-mutant tumor cells could potentially inform the development of new therapeutic approaches to this disease. Recently the methyltransferase, EZH2 and PARP inhibitors have been proposed as therapeutic targets in ARID1A-mutant tumors (14, 15) and synthetic lethality...
between ARID1A and ARID1B has also been described (16). Here, we describe a high-throughput functional genomics approach to screen a series of clinically used drugs with the intention of identifying novel ARID1A synthetic lethal effects (17) that operate in OCCC. By profiling drugs that are either already used in the clinical management of cancer or compounds with targets that are currently in late-stage development, we also aimed to identify ARID1A synthetic lethal approaches that could potentially be rapidly translated in the clinic.

Materials and Methods

Reagents and cell lines

Dasatinib was purchased from Selleck chemicals. Additional drugs and small-molecule inhibitors used in this study are listed in Supplementary Table S1. ES2 and TOV21G were obtained from the ATCC. RMG-1, SMOV2, KOC7C, HCH1, OVAS, OVISE, OVMANA, OVTOKO, and KK were provided by Dr. Hiroaki Itamochi (Tottori University School of Medicine, Yonago, Japan). Ovarian clear cell lines were grown in RPMI with 10% FCS. The identity of cell lines was confirmed by STR typing using the StemElite Kit (Promega) in March 2013 and where appropriate, profiles were confirmed using the Children’s Oncology Group (COG) Cell Culture and Xenograft Repository bank (http://strdb.cogcell.org) or JCRB cell bank (http://cellbank.nibiohn.go.jp/english/). ARID1A HCT116 were grown in McCoy media with 10% (v/v) FCS. Arid1a-null and wild-type mouse embryonic stem cells were provided by Dr. Zhong Wang (Harvard Medical School, Boston, MA; ref. 9) and grown on gelatin-coated plates in DMEM with 10% (v/v) FCS supplemented with 0.1 mmol/L nonessential amino acids, 1 mmol/L sodium pyruvate, 0.1 mmol/L beta-metacaptothanol, and 2,000 U LIF/mL. All cell lines were routinely replaced every three days. After 14 days, cells were washed twice with cold binding buffer and then an additional three times with binding buffer with reduced NaCl minus detergent. Proteins were eluted with 6 mol/L urea and trypsinized, desalted, and analyzed by LC-MS/MS on a Thermo LTQ Orbitrap Velos. Spectra were searched using Protein Prospector and label-free quantitation performed with Skyline. Significance of effects was determined using MS Stats (21).

High-throughput drug screen

Cell lines were profiled using a customized drug library (Supplementary Materials and Methods) containing 68 compounds (Supplementary Tables S2 and S3). Cells were plated at a density of 250 or 500 cells per well. Twenty-four hours later, media containing drug library were added to adherent cells. On day seven, cell viability in each well was estimated using CellTiter-Glo (Promega). Surviving fractions (SF) were calculated relative to DMSO-treated wells, and drug sensitivity curves plotted. Where appropriate, surviving fractions were calculated relative to DMSO-treated wells and these data were used to generate AUC and SF50 data.

Cell-based assays

Short-term drug exposure assays were performed in 96-well plates. Cells were plated at a density of 250–500 cells/well and drug added at the indicated concentration 24 hours later. Cell viability was estimated after seven days using CellTitre Glo (Promega). Surviving fractions (SF) were calculated relative to DMSO-treated wells, and drug sensitivity curves plotted.

Clonogenic assays were performed in triplicate in 6-well plates. OCCC cell lines were plated at a density of 500 cells/well and mouse embryonic stem (ES) cells were plated at a density of 2,000 cells per well on gelatin-coated plates. Media containing dasatinib at the indicated concentrations were replaced every three days. After 14 days, cells were fixed in 10% trichloroacetic acid and stained with sulforhodamine-B prior to counting.

siRNA experiments

A 384-well plate arrayed siRNA library targeting 784 genes (Dharmacon) was used (gene list described in Supplementary Table S4) or a bespoke Dharmacon siRNA library of dasatinib targets. Each well either contained a SMART pool (four distinct siRNA species targeting different sequences of the target transcript combined) or a single siRNA species. Additional positive (siPLK1) and negative [siCON1, siCON2 and Allstar (Dharmacon and Qiagen, respectively)] controls were also added to each plate. Cells were reverse transfected using Dharmafect4 (Dharmacon). Forty-eight hours after transfection, media containing dasatinib or the drug vehicle, DMSO, were added to the plates. After seven days, cell viability in each well was estimated using a CellTiter-Glo assay. Data were processed as described in Supplementary Materials and Methods and as in ref. 18.

Dasatinib bead proteomics

Inhibitor bead proteomics was performed as described previously (19, 20). Dasatinib was covalently linked to ECH sepharose 4B using EDC and then 1 mg of precleared cell lysate was rotated with 50 μL of dasatinib bead slurry for three hours. Beads were washed twice with cold binding buffer and then an additional three times with binding buffer with reduced NaCl minus detergent. Proteins were eluted with 6 mol/L urea and trypsinized, desalted, and analyzed by LC-MS/MS on a Thermo LTQ Orbitrap Velos. Spectra were searched using Protein Prospector and label-free quantitation performed with Skyline. Significance of effects was determined using MS Stats (21).

Protein analysis

Cells were lysed, electrophoresed, and immunoblotted as described previously (22). We used the following antibodies: ARID1A [Bethyl A301-040A (human) and Santa Cruz Biotechnology sc-32761 (mouse)] α-Actinin (A5044, Sigma), Actin (sc-1616, Santa Cruz Biotechnology), β-Tubulin, (2146, Cell Signaling Technology), YES1 (3201S, Cell Signaling Technology), and CDKN1A (2947, Cell Signaling Technology). All secondary antibodies were horseradish peroxidase conjugated. Primary antibodies were used at a concentration of 1:1,000 and secondary antibodies at a concentration of 1:10,000. Protein bands were visualized using enhanced chemiluminescence (ECL, GE Healthcare) and Kodak BioMAX XR film (Kodak). Alternatively, lysates were probed with the primary antibody and a fluorescent dye-labeled secondary antibody and images were taken using the Odyssey Infrared Imaging system from LI-COR.

Exome sequencing

BWA (Burrows-Wheeler Aligner, bio-bwa.sourceforge.net) was used to align short reads to a reference sequence (GRCh37). Duplicate sequence reads (PCR-derived duplicates) were removed from further analysis at this point. Base quality recalibration, realignment around indels, and variant calling were performed using the Genome Analysis Tool Kit (GATK) using the Broad best practice variant detection workflow (www.broadinstitute.org/gatk/guide/best-practices). Small insertions and deletions detected in the tumor cell lines that were absent in the reference genomes were considered to be candidate somatic mutations. The set of candidate somatic mutations was refined using the...
following list of heuristic rules: (i) variants called in regions not covered by the exome capture probes were excluded; (ii) variants marked as low quality (QQUAL below 20) were excluded; (iii) variants with fewer than 10 reads covering the locus in all samples were excluded. Common SNPs (those reported to have a global minor allele frequency of greater than 5% in any of the 1000 genomes project data sets) were also removed from the main analysis. The remaining variants were annotated using the Ensembl variant effect predictor script (Ensembl v61).

**Cell-cycle analysis**

Cells were plated at a density of $2 \times 10^6$ cells per well of a 6-well plate and incubated for 24 hours after which dasatinib or 0.1% (v/v) DMSO was added to the media and cells cultured for a further 24 hours. After incubation, both adherent and free-floating cells were harvested and then fixed overnight with cold 70% (v/v) ethanol. Cells were then treated with RNase A for 30 minutes prior to nucleic acid staining with propidium iodide (PI, Sigma). Samples were analyzed on a BD LSR II flow cytometer using BD FACSDiva software (BD Biosciences).

**Apoptosis assay**

After 48-hour dasatinib exposure, cells were analyzed using the ApoTox-Glo Triplex Assay (Promega) as per the manufacturer’s instructions.

**In vivo efficacy studies**

For the biomarker study, TOV21G cells were used to generate subcutaneous xenografts in nu/nu athymic female mice. Once tumors were established ($\geq 500$ mm diameter), treatment with dasatinib was initiated for 72 hours. Dasatinib was either dissolved in 80 mmol/L sodium citrate at pH 3 for administration via oral gavage or dissolved in DMSO for intraperitoneal injections. Three animals received oral dasatinib at a dose of 15, 30, or 45 mg/kg/day and three animals received dasatinib at a dose of 5, 10 or 15 mg/kg/day i.p., the remaining animals served as a control. Three animals received oral dasatinib at a dose of 15, 30, or 45 mg/kg/day in sodium citrate (80 mmol/L) via oral gavage for 72 hours. Dasatinib was either dissolved in 80 mmol/L sodium citrate at pH 3 for administration via oral gavage or dissolved in DMSO for intraperitoneal injections. Three animals received oral dasatinib at a dose of 15, 30, or 45 mg/kg/day and three animals received dasatinib at a dose of 5, 10 or 15 mg/kg/day i.p., the remaining animals served as a control and were not treated. Two hours after the final drug administration, animals were culled; tumor and normal tissue (spleen and liver) were then collected. Tissues were then thinly sliced and mixed with RIPA buffer in a cryotube overnight at 4°C. Samples were then homogenized and spun in a centrifuge at 15,000 rpm for 15 minutes. The supernatant was then removed and protein quantified using Bio-Rad Protein Assay Reagent (Bio-Rad).

TOV21G cells were transfected with a luciferin expression lentivirus (LVp433 Amsbio) and maintained in blasticidin selection (25 μg/mL) for 10 days prior to injection into female athymic nu/nu mice. A total of $1.0 \times 10^6$ TOV21G cells in 100 μL of PBS were injected directly into the peritoneal cavity of 40 nu/nu athymic female mice. Treatment with dasatinib ($n = 20$) or vehicle ($n = 20$) was initiated 24 hours after tumor injection. Mice received either dasatinib 15 mg/kg in sodium citrate (80 mmol/L) via oral gavage or vehicle treatment (sodium citrate) daily. Prior to IVIS imaging, luciferin 150 mg/kg (PerkinElmer) was injected into the peritoneal cavity. Mice were culled when they exhibited signs of distress or >20% weight loss or gain (secondary to ascites).

**Results**

**Identification of ARID1A-selective drugs using a focused drug screen**

We aimed to identify existing drugs that could selectively target ARID1A-mutant OCCC. To do this, we designed a high-throughput drug sensitivity screen (Fig. 1A), where we profiled the in vitro sensitivity of a range of tumor cell models of OCCC to 68 drugs many of which are currently used in the treatment of cancer or are in late-stage development. To facilitate this, we first characterized a panel of commonly used OCCC tumor cell models according to their ARID1A gene mutation and protein expression status. Using whole exome sequencing and immunoblot analysis, we confirmed the previously documented (23, 24) presence of truncating ARID1A mutations and loss of full-length ARID1A protein expression in SMOV2, OVISE, TOV21G, OVTOKO, OVMANA, KOC7C, OVAS, and HCH1. OCCC cell line models (Supplementary Figs. S1 and S2; Supplementary Table S5). We also confirmed the expression of full-length ARID1A protein and the absence of ARID1A gene mutations in ES2, KK, and RMG-1 models of OCCC (Supplementary Figs. S1A and S1B and S2; Supplementary Table S5). This characterization allowed us to define two cohorts of OCCC tumor cell models for further analysis: ARID1A mutant (deficient; SMOV2, OVISE, TOV21G, OVTOKO, OVMANA, KOC7C, OVAS and HCH1) and ARID1A wild-type (ES2, KK, and RMG-1).

Using these OCCC tumor cell lines, we carried out a series of parallel high-throughput drug sensitivity screens (HTS). As a screening library, we used an in-house curated collection of 68 drugs that were selected on the basis of being either already used in the treatment of cancer or being in late-stage development (Supplementary Table S2). Each tumor cell line was plated in a 384-well plate format and then 24 hours later, exposed to each drug for a subsequent five days. At the end of this five-day period, we estimated cell viability by the use of a CellTiterGlo (CTG) assay (Fig. 1A). Each of the 11 OCCC tumor cell lines was screened in triplicate, with replica drug sensitivity data from each cell line being highly reproducible as shown by Pearson correlation coefficients between screen replicates of > 0.75 (Fig. 1B and Supplementary Table S6). The dynamic range of each screen was also estimated by calculating Z prime (Z’) values for data from each 384-well plate used in the screen. To calculate Z’ values, we compared CTG luminescent readings from DMSO (cell inhibition negative control) exposed cells to CTG luminescence readings from wells where cells were exposed to 5 μmol/L puromycin (cell inhibition–positive control). Each 384-well plate in the screen delivered a Z’ > 0.5 (Fig. 1C; Supplementary Table S6), confirming a suitable dynamic range for each plate used in the screen. To maximize the potential for identifying ARID1A synthetic lethal effects, we screened each cell line using four different drug concentrations (1 nmol/L, 10 nmol/L, 100 nmol/L, and 1 μmol/L) and used these data to generate dose/response survival data for each drug in each cell line model (Supplementary Table S7). These data were then used to calculate AUC for each drug in each tumor cell line as well as SF50 (surviving fraction 50—the concentration of drug required to elicit a 50% inhibition of the cell population) estimates of drug sensitivity (Supplementary Fig. S3A and S3B) of each OCCC tumor cell line.

By comparing the median AUC values in ARID1A wild-type and mutant cohorts, we identified drugs predicted to deliver an ARID1A-mutant–selective effect. The most profound effect identified in this way was elicited by dasatinib (BMS-354825; Fig. 1D and E). When defining the differential drug sensitivities in ARID1A-mutant versus wild-type cohorts by comparing median AUC values, dasatinib showed a distinct effect, with an AUC of $4 \times 10^{-6}$ in the ARID1A-mutant cohort versus $1 \times 10^{-5}$ in the ARID1A wild-type cohort (Fig. 1D and E), an effect also observed by the
Figure 1.
Identification of ARID1A-selective drugs using a focused drug screen. A, focused drug high-throughput screen (HTS) schematic. Eight ARID1A-mutant and three ARID1A wild-type OCCC cell lines were plated in triplicate 384-well plates and, 24 hours later, media containing compound library were added to the 384-well plates. Cells were continuously cultured for a subsequent five days after which cell viability was estimated using a luminescence assay (CellTiter-Glo, Promega). After processing data (see Materials and Methods), the screen quality control was assessed by examining the correlation between data from replica screens (example shown in B) and Z prime statistics for each plate and each screen replica (example shown in C). B, example, scatter plot of drug sensitivity data from replica ES2 cell line screens. C, example, Z prime values for replica ES2 screens (R1 = replica 1). The distribution curve on the left represents the data from positive control (siPLK1) and the curve on the right is from negative controls (siCON). D and E, waterfall and box-whisker plots of dasatinib AUC data from the high-throughput screen. Median ARID1A-mutant AUC = 4 x 10\(^{-6}\) and wild-type = AUC 1 x 10\(^{-5}\). Waterfall (F) and box-whisker (G) plots of dasatinib SF50 data from the high-throughput screen. Median ARID1A mutant SF50 = 271 nmol/L as opposed to wild-type SF50 = 707 nmol/L.
Dasatinib is a synthetic lethal drug in ARID1A-mutant OCCC tumor cell line models

To validate the ARID1A selectivity of dasatinib identified in the high-throughput screens, we carried out both short- and as long-term drug sensitivity experiments in our panel of OCCC tumor cell lines. We found that a relatively short six-day exposure to dasatinib was selective for ARID1A-mutant OCCC models (Fig. 2A and B and Supplementary Fig. S5A and SSB, two-way ANOVA, ARID1A-mutant vs. wild-type cohorts; P < 0.05) as was a longer-term, 15-day drug exposure (Fig. 2C and D and Supplementary Fig. S5C and S5D, two-way ANOVA, ARID1A-mutant vs. wild-type cohorts in Fig. 2C; P < 0.0001).

Although we found dasatinib to preferentially target the ARID1A-mutant cohort of OCCC models, the possibility existed that other genetic variants in the tumor cell line panel might explain the sensitivity to dasatinib. To independently establish whether ARID1A was indeed a determinant of dasatinib sensitivity, we assessed drug sensitivity in three different isogenic model systems in which we engineered either ARID1A depletion or mutation. In the parental ARID1A wild-type clone (ARID1AWT/WT), we carried out a subsequent high-throughput drug screen using a second compound library which included the original screening library with the addition of a number of supplementary drugs (Supplementary Tables S3 and S8). Three different concentrations of dasatinib (1,000 nmol/L, 500 nmol/L, and 100 nmol/L) were ranked within the ten most profound ARID1AQ456/C3Q456 selective effects (Supplementary Fig. S6C). This finding was confirmed in a subsequent validation assay (Supplementary Fig. S6D, two-way ANOVA, P < 0.001; ARID1AQ456/C3Q456 cells compared with the parental ARID1AWT/WT model).

Having confirmed the validity of the ARID1A/dasatinib synthetic lethality, we assessed whether this effect could be explained by hyperactivity and/or addiction to dasatinib targets. In the first instance, we used an unbiased activity-based proteomics approach to estimate the relative activity of all dasatinib-binding kinases in a subset of our OCCC panel. This ‘inhibitor bead’ approach is based upon the use of an ATP-competitive kinase inhibitor (in this case dasatinib) covalently linked to sepharose. As the ATP-binding avidity of protein kinases is increased by the allosteric changes that follow kinase activation, the relative amount of particular kinases bound to sepharose-dasatinib beads (measured by mass spectrometry) can be used to estimate kinase activity (Fig. 3A; refs. 19, 30, 31). Using this approach, we profiled OVISE, KK, RMG1, and TOV21G cells and found that five dasatinib targets (Epha2, MAP4K5, ABL2, YES1, and ABL1) were enriched (P < 0.01) in the ARID1A-mutant cell lines compared with the wild-type cells (Fig. 3B; Supplementary Tables S9 and S10).

Although these data suggested that ARID1A-mutant tumor cell lines exhibited enhanced activity of a number of dasatinib targets, it did not formally confirm addiction to EPHA2, MAP4K5, ABL2, YES1, or ABL1. Therefore, in parallel with this proteomic assessment, we also used a genetic approach and assessed the addiction of 10 OCCC tumor cell lines (three ARID1A wild-type and seven ARID1A-mutant models) to dasatinib targets (Fig. 3C). We selected 14 dasatinib targets that have dasatinib dissociation constants (Kd) of <1 nmol/L (32) and are inhibited at clinically relevant concentrations (ref. 33; Supplementary Table S11) and profiled each tumor cell model with this library. Using this data, we were able to calculate median NPI values for both the ARID1A-mutant OCCC cell line cohort (SMOV2, OVISE, TOV21G, OVMANA, KOC7C, OVAS, and HCH1) as well as the ARID1A wild-type cohort (KK, ES2, and RMG1; Fig. 3C). By comparing the cell-inhibitory effects caused by each siRNA in ARID1A wild-type and mutant cohorts, we identified likely ARID1A synthetic lethal effects (Supplementary Table S11; Fig. 3D and Supplementary Fig. S7A). We noted that the most consistent ARID1A-selective effect (i.e., where the ARID1A-selective effect was observed with multiple different siRNAs) was caused by siRNA designed to target YES1 (Fig. 3D). Three of the YES1 individual siRNA species and the YES1 siRNA SMARTpool ranked within the ten most profound ARID1A-selective effects, as defined by the median difference in NPI (Fig. 3E and F and Supplementary Figs. S2 and S7B; Supplementary Table S11). We also found that the YES1 siRNA SMART-pool and individual YES1 siRNAs selectively targeted the ARID1AQ456/C3Q456 parental clone (Supplementary Fig. S7C), suggesting that ARID1A mutation might indeed cause dependency upon
Figure 2. Dasatinib is a synthetic lethal drug in ARID1A mutant OCCC tumor cell line models. A, median dasatinib SF dose–response curves in ARID1A-mutant and wild-type cohorts. Cells were plated in 96-well plates and exposed to dasatinib for five days after which SF were calculated. Data in A represents median of six replicates per cell line. Error bars, SEM. Dasatinib response in ARID1A-mutant versus wild-type cohort; two-way ANOVA, *P* < 0.0001. B, waterfall plot showing the individual dasatinib SF50 for each OCCC cell line (nmol/L). C, clonogenic (15-day exposure) dasatinib response in ARID1A-mutant vs. wild-type cohort; two-way ANOVA, *P* < 0.0001. D, representative clonogenic assay images from two ARID1A wild-type and two ARID1A-mutant cell lines exposed to dasatinib. E, Western blot analysis of Arid1a expression from whole-cell lysates in Arid1a isogenic mouse ES cells. Tubulin is included as a loading control. F, dasatinib dose–response survival data from clonogenic experiments in isogenic ES cells. Cells were plated on gelatin-coated plates and exposed to dasatinib for 14 days. Error bars, SEM from six replicas per cell line. SF for the Arid1a-null versus Arid1a wild-type mouse ES cells; two-way ANOVA, *P* < 0.001. G, dasatinib dose–response survival data from the ARID1A wild-type cells (ES2) transfected with siRNA targeting ARID1A. Forty-eight hours after transfection, cells were plated into 96-well plates and exposed to dasatinib for five days. Error bars, SEM from six replica experiments. H, Western blot analysis of ARID1A expression from whole-cell lysates (ES2) transfected as described in G. Tubulin is included as a loading control.
Dasatinib target screen performed in 384-well plates in quadruplicate. Normalized percent inhibition calculated for each siRNA. Cellular viability measured day 5 with luminescent assay. Cell lines reverse transfected with either siRNA SMART pool or individual oligo. Identification of ARID1A synthetic lethal effect.

Figure 3.
ARID1A-mutant cell line models and YES1 addiction. A, schematic of inhibitor bead approach: active kinases are preferentially purified by dasatinib coupled to sepharose and analysed by LC/MS/MS. Label-free quantification with MS1 filtering is used to determine relative representation of each peptide. B, scatter plot of dasatinib-bound kinase abundance from pooled biologic replicates (two each) of ARID1A wild-type (KK, RMG-1) and mutant (OVISE, TOV21G) tumor cell lines. Axis represents median centered abundance; statistically significant ratios between ARID1A-mutant and wild-type cell lines (adjusted \( P < 0.05 \)) are shown in red. C, dasatinib target siRNA screen overview. Ten OCCC cell lines were included in the screen. Each cell line was reverse transfected with either a SMARTpool of four siRNAs designed or individual siRNA species (four per gene) in a 384-well plate. The siRNA library targeted known targets of dasatinib. After siRNA transfection, cells were cultured for a subsequent five days at which point cell viability was estimated by the use of Cell TiterGlo Reagent. To estimate the extent to which each siRNA caused tumor cell inhibition, normalized percent inhibition (NPI) values for each siRNA were calculated and median NPI values between ARID1A wild-type and mutant cohorts compared. D, heatmap showing NPI data from the dasatinib target siRNA screen. Individual siRNAs are ranked according to difference in NPI between ARID1A-mutant and wild-type cohorts. The ten most profound ARID1A-selective are highlighted. E, bar chart plot of YES1 NPI values from the screen. Median NPI values from each cohort are shown; error bars, SEM. In each case, the NPI in the ARID1A-mutant cell line was significantly less than in the wild-type model (\( P < 0.05 \), Student’s t test). F, Western blot analysis demonstrating YES1 silencing caused by each individual siRNA species in the OVISE cell line. The OVISE cell line was transfected with either control siRNA, individual YES1 siRNAs, YES1 SMARTpool, or mock transfected. Forty-eight hours after transfection, whole-cell lysates were collected. Western blots were probed for YES1 and ACTIN was included as a loading control.
YES1, an observation that could explain the sensitivity of ARID1A-mutant tumor cells to dasatinib. We confirmed that YES1 activation was reduced at relevant dasatinib concentrations (Supplementary Figs. S2, S7D, and S7E). However, the addiction to YES1 in ARID1A-mutant cell lines could not be explained by baseline differences in expression levels between the ARID1A wild-type and mutant cohorts (Supplementary Fig. S2 and S2E, S2F).

Dasatinib sensitivity in ARID1A-mutant OCCC is characterized by an apoptotic response

One of the known phenotypic effects of dasatinib exposure in tumor cell lines is the induction of G1 cell-cycle arrest followed by cell apoptosis (34–39). To understand whether a similar effect might explain the ARID1A/dasatinib synthetic lethality, we assessed cell-cycle progression and the extent of apoptosis in two ARID1A-mutant and two wild-type OCCC models. This was carried out using propidium iodide and Annexin V staining, followed by FACS. We observed a modest but significant increase in dasatinib-induced G1 arrest in the ARID1A-mutant models, HCH1 and OVISE compared with wild-type models, ES2 and KK (Fig. 4A, P < 0.05 in each wild-type vs. mutant comparison, Student t test). There was, however, a more profound apoptotic response to dasatinib in the ARID1A-mutant models suggesting that although a cell-cycle response could form part of the

Figure 4. Dasatinib sensitivity in ARID1A-mutant OCCC is characterized by G1 arrest and an apoptotic response. A, column chart illustrating the proportion of cells in different phases of the cell cycle when exposed to dasatinib. Exposure to dasatinib led to a significant increase in the proportion of cells in the G1 phase of the cell cycle in the ARID1A-mutant cell lines HCH1 and OVISE but not the ARID1A wild-type cell lines ES2 and KK. Cells were exposed to 50 nmol/L dasatinib for 24 hours and fixed in 70% ethanol prior to propidium iodide staining and FACS analysis. Error bars, ± SD from n = 3 independent experiments. S-phase fraction in ARID1A-mutant tumor cells is significantly reduced by dasatinib exposure (Student t test; P < 0.05, for both OVISE and HCH1). B, bar chart illustrating caspase-3/7 activity in response to dasatinib. Cells were treated as in A and caspase-3/7 activity assessed using the ApoTox Glo triplex assay (Promega). P values for ARID1A-mutant cells (OVISE and TOV21G) cells versus ARID1A wild-type (ES2 and KK) (**, P < 0.001; *, P < 0.01; ns, not significant; Student t test).

Dasatinib sensitivity in ARID1A-mutant OCCC is p21 and RB depending and is characterized by an apoptotic response

One of the known phenotypic effects of dasatinib exposure in tumor cell lines is the induction of G1 cell-cycle arrest followed by
Dasatinib is selective for ARID1A-mutant OCC tumors in vivo

We generated an in vivo model of ARID1A-mutant OCC by subcutaneously xenografting the TOV21G ARID1A-mutant OCC cell line (ARID1A p.S48fs (p.756fs)) into immunocompromised recipient mice. This led to the growth of very aggressive, highly proliferative, subcutaneous tumors. This approach allowed us to assess the effect of dasatinib on these tumors. Published reports on the use of dasatinib in mice vary greatly in terms of the route of administration (oral gavage or intraperitoneal injections) as well as in the dasatinib dose used (42–44). Therefore, to identify a dose and route of administration that would minimize the impact of deleterious side effects while still delivering an effective dose, we first conducted a biomarker study. Subcutaneous TOV21G tumors were established in nu/nu athymic mice and animals were treated with dasatinib using either oral gavage or intraperitoneal (i.p.) routes of administration at a range of concentrations (oral administration of 15, 30, or 45 mg/kg per day or intraperitoneal administration of 5, 10, or 15 mg/kg per day). By estimating the extent of SRC phosphorylation as a biomarker of dasatinib activity, we were able to predict whether dasatinib elicited a mechanistic effect in both tumor and normal tissue (Supplementary Fig. S10). At each dasatinib dose tested and using either oral or intraperitoneal administration, SRC phosphorylation was completely abolished in both tumor and normal tissue (Supplementary Fig. S10) and was well tolerated in each case. We therefore selected the lowest dose of dasatinib (15 mg/kg) for subsequent studies and administered this via an oral route.

On the basis of these data, we assessed the in vivo antitumor efficacy of dasatinib. To do this, we first labeled ARID1A-mutant TOV21G cells with a luciferase-expressing construct so that we could later visualize the extent of tumor burden in live animals by the use of an In Vivo Imaging System (IVIS, PerkinElmer). These labeled cells were then xenografted into recipient mice where they generated widespread miliary (disseminated) peritoneal disease (Fig. 4B and Supplementary Fig. S8). We also found that silencing of RB1, a key cycle regulator, isogenic clones. Transfection of each individual siRNA and the SMARTpool were transfected into two ARID1A-mutant OCC cell lines and the ARID1A isogenic clones. Transfection of each individual siRNA and the SMARTpool led to dasatinib resistance in both of the cell lines examined suggesting an on-target effect (Fig. 5C) and Western blot analysis confirmed CDKN1A silencing (Fig. 5D and Supplementary Fig. S2). We also found that silencing of RB1, a key modulator of the G1–S checkpoint also caused dasatinib resistance in multiple ARID1A-mutant OCC cell lines and the isogenic HCT116 ARID1A455fs (p.Q5fs)–mutant (Supplementary Figs. S2 and S9B–S9E), supporting the hypothesis that in ARID1A-null tumor cells, the inhibitory effect of dasatinib is mediated via the activity of CDKN1A and RB1.

Discussion

Ovarian cancer is the most lethal gynecologic malignancy. The OCC subtype presents a particular clinical management challenge as it is invariably characterized by resistance to standard chemotherapy as well as a poor prognosis (1). In the work presented here, we have attempted to understand drug sensitivities associated with ARID1A mutation in OCC by using a functional genomics approach. This has led us to the identification of dasatinib as a candidate synthetic lethal drug in ARID1A-mutant OCC. Dasatinib is not only selective for ARID1A-mutant OCC models, but experimental induction of ARID1A deficiency drives dasatinib sensitivity in ARID1A wild-type OCC models as well as in isogenic cell systems (both mouse and human) where ARID1A has been rendered dysfunctional by gene targeting. The selectivity of dasatinib in this context appears to be characterized by a cell-cycle arrest/apoptotic functional phenotype, which can be reversed with silencing of either CDKN1A or RB1.
Figure 5.
Dasatinib sensitivity in ARID1A-mutant OCCC is dependent upon G1–S checkpoint effectors. A, drug effect (DE) Z score distribution plots from two independent dasatinib resistance siRNA screens in OVISE tumor cells. Data from SF50 (left) and SF16 (right) dasatinib-resistant screens are shown. CDKN1A and RB1 siRNA effects are highlighted, driving dasatinib resistance in each screen. B, dasatinib dose–response curves for the ARID1A-mutant OCCC cell line OVISE and the ARID1A wild-type cell line ES2 following transfection with the CDKN1A siRNA SMARTpool. Silencing of CDKN1A expression results in dasatinib resistance. Each point represents the mean and SEM of six replicates. CDKN1A siRNA dasatinib survival curve versus control siRNA two-way ANOVA; \( P < 0.0001 \) for OVISE and \( P = 0.02 \) for ES2. C, dasatinib dose–response curves for the ARID1A-mutant OCCC cell line OVISE and the ARID1A\(^{Q456*/Q456^*} \) isogenic clone after transfection with four individual CDKN1A siRNA oligos and the CDKN1A SMARTpool. Each of the individual siRNAs results in dasatinib resistance suggesting that the effect observed is not due to an off-target effect. For each CDKN1A siRNA, dasatinib survival curve versus control siRNA (two-way ANOVA, \( P < 0.001 \)). D, Western blot analysis demonstrating the on-target nature of the CDKN1A siRNA. OVISE cell line was transfected with CDKN1A siRNA and whole-cell lysates collected 48 hours later. Lysates were probed with the p21 antibody and a fluorescent dye–labeled secondary antibody used.
Miller et al.

ARID1A has previously been demonstrated to act as a negative regulator of the cell cycle (10, 24, 45). In part, this effect has been ascribed to an impairment of p21-mediated cell-cycle control in ARID1A-null cells (24). Taking this into account, along with the data presented here, and the known role of dasatinib in p21 induction (34, 36, 46), one possibility is that dasatinib targets ARID1A-null tumor cells because it reverses p21 dysfunction caused by ARID1A deficiency. The work presented here suggests that the dasatinib sensitivity of ARID1A-null models is somewhat dependent upon p21 and RB1, observations that are consistent with this hypothesis. It is possible that the sensitivity to dasatinib might be related to a dependency upon the dasatinib target YES1 that we have observed, although we cannot discount the possibility that other dasatinib targets might also be involved or that combinations of dasatinib targets might play a role in the phenotype we observe. We do note that an analysis of microarray-based mRNA profiles from the ARID1A wild-type and mutant tumor cell lines described in this report and publicly available transcriptomic profiles of ARID1A-mutant OCCC did not identify a canonical signaling process that was distinct between wild-type and mutant cohorts (R.E. Miller, C.J. Lord, A. Ashworth, unpublished observations). Although the correlation between ARID1A genotype and dasatinib sensitivity are striking, being present in not only the panel of OCCC models but also in isogenic systems, we noted that one of the ARID1A-mutant OCCC cell lines, KOC7C, was relatively resistant to dasatinib but addicted to YES1. It is possible that while the ARID1A defect in KOC7C is sufficient to drive YES1 addiction, other genetic or epigenetic factors in this cell line modulate the ARID1A/dasatinib synthetic lethality.

Our assessment of dasatinib efficacy suggests that there are promising signs that dasatinib can inhibit ARID1A-mutant tumors in vivo, although it is clear that further work is required to optimize how dasatinib might be used to elicit a profound, long-lasting antitumor response in women with OCCCs. For example, using additional OCCC cell lines (both ARID1A wild-type and mutant) as established orthotopic tumors (as opposed to nonestablished tumors shown in Fig. 6) would extend the observations made using the TOV21G model. It also seems reasonable to suggest that combination therapy approaches involving dasatinib might be used to maximize the therapeutic window as well as minimizing the impact of signaling feedback loops that might impair the therapeutic effect of dasatinib. In this regard, one clear objective for future in vivo assessment will be to assess the possibility that the therapeutic window caused by dasatinib could be enhanced by combining this kinase inhibitor with other proposed ARID1A synthetic lethal drugs such as EZH2 and PARP inhibitors (14, 15). It might also be pertinent to assess the impact of tumor heterogeneity on the dasatinib therapeutic response. In this case, subsequent studies assessing the effect of dasatinib in mice bearing ARID1A-mutant human patient derived xenografts (PDX) might be appropriate, given that PDX material has the capacity to reflect the molecular heterogeneity of human tumors.

Dasatinib is already licensed for use for the treatment of chronic myelogenous leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (AML; refs. 47, 48). Several clinical trials have also been conducted, or are at least underway, in patients with solid tumors. In these solid tumor clinical trials, dasatinib is being assessed either as a single-agent therapy or is being assessed when used in combination with cytotoxic or other targeted therapies (49). However, to date, there has been limited success in using dasatinib in the treatment of ovarian cancer patients. When dasatinib was assessed as a single-agent therapy in patients with relapsed epithelial ovarian cancer, minimal antitumor activity was observed, although we note there were only two patients with OCCC in this study, neither of which had known ARID1A status (50, 51). In a recent phase 1 clinical trial using dasatinib in combination with standard cytotoxic chemotherapy (carboplatin and paclitaxel), the drug combination regime could be delivered safely and some evidence of clinical efficacy was achieved (50, 51). Of course, neither of these trials were designed to test the hypothesis that ARID1A-mutant OCCC might respond to dasatinib therapy and based upon the work we describe in this manuscript, we believe that testing this hypothesis is warranted.

Disclosure of Potential Conflicts of Interest
No potential conflicts of interest were disclosed.

Authors’ Contributions
Conception and design: J.D. Gordan, C.J. Lord, A. Ashworth
Development of methodology: H. Astley, C. Mahoney, C. Torrance, K.M. Shokat, C.J. Lord
 Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): R.E. Miller, I. Bajrami, C.T. Williamson, S. McDade, A. Kigozi, H. Pemberton, R. Natrajan, J. Joel, H. Astley, C. Mahoney, J.D. Moore, J.D. Gordan, R.S. Levin, C.J. Lord
Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): R.E. Miller, J. Bajrami, C.T. Williamson, J. Campbell, J.D. Gordon, J.T. Webber, R.S. Levin, K.M. Shokat, S. Bandyopadhyay, C.J. Lord, A. Ashworth

Writing, review, and/or revision of the manuscript: R.E. Miller, J.D. Moore, J.D. Gordon, K.M. Shokat, C.J. Lord, A. Ashworth

Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): R. Brough, I. Bajrami, A. Kigozi, R. Rafiq

Study supervision: C.J. Lord, A. Ashworth

Acknowledgments
The authors thank Prof. Stan Kaye (ICR and Royal Marsden Hospital, London, United Kingdom) for useful discussions and Dr. Zhong Wang (Harvard Medical School, Boston, MA) for providing Arid1a-null and wild-type mouse ES cells.

Grant Support
This work was supported by grants to A. Ashworth and C.J. Lord from Cancer Research UK (C347/A8363). Breast Cancer Now, and the European Union as part of the EUROcan FET programme (HEALTH-FP7-2010-260791). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received July 6, 2015; revised April 4, 2016; accepted April 6, 2016; published Online First June 30, 2016.

References

Dasatinib/ARID1A Synthetic Lethality in OCCC

Published OnlineFirst June 30, 2016; DOI: 10.1158/1535-7163.MCT-15-0554

Mol Cancer Ther; 15(7) July 2016
1483

www.aacajournals.org

Downloaded from mct.aacrjournals.org on June 28, 2019. © 2016 American Association for Cancer Research.


Molecular Cancer Therapeutics

Synthetic Lethal Targeting of ARID1A-Mutant Ovarian Clear Cell Tumors with Dasatinib

Rowan E. Miller, Rachel Brough, Ilirjana Bajrami, et al.


Updated version
Access the most recent version of this article at:
doi:10.1158/1535-7163.MCT-15-0554

Supplementary Material
Access the most recent supplemental material at:
http://mct.aacrjournals.org/content/suppl/2016/05/24/1535-7163.MCT-15-0554.DC1

Cited articles
This article cites 51 articles, 17 of which you can access for free at:
http://mct.aacrjournals.org/content/15/7/1472.full#ref-list-1

Citing articles
This article has been cited by 4 HighWire-hosted articles. Access the articles at:
http://mct.aacrjournals.org/content/15/7/1472.full#related-urls

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, use this link
http://mct.aacrjournals.org/content/15/7/1472.
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.